Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 15.01 crore in Q1FY23
Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd
Business Highlights:-
Total Income in Q1FY23 at Rs. 129.97 crore, up 24.4% from Rs. 104.4 crore in Q4FY22
Commercial operations of Cephalosporin Plant and Export to EU & Australia to commence in FY23
Company continuous to remain 'Net Debt Free' after multiple expansion & acquisition of Cephalosporin plant
Robust operational and financial performance during FY12 to FY22 with CAGR Growth 30% in Net profits, 20% in EBITDA and 10% in Revenue.
CRISIL has upgraded its ratings on the company's bank facilities to ‘CRISIL A/Stable/CRISIL A1
Ahmedabad, August 9, 2022: Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has reported net profit of Rs. 15.01 crore for the Q1FY23 as against net profit of Rs...